Maxim Group Remains a Buy on Ra Medical Systems (RMED)

By Ryan Adsit

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Ra Medical Systems (RMEDResearch Report) yesterday and set a price target of $3.00. The company’s shares closed last Monday at $1.28, close to its 52-week low of $1.06.

According to, Vendetti is a 2-star analyst with an average return of 0.0% and a 43.4% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Milestone Scientific, Sensus Healthcare, and Zosano Pharma.

The word on The Street in general, suggests a Hold analyst consensus rating for Ra Medical Systems with a $1.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $10.19 and a one-year low of $1.06. Currently, Ra Medical Systems has an average volume of 60.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ra Medical Systems, Inc. engages in the design, development, and commercialization of excimer lasers for the treatment of dermatologic and cardiovascular diseases. Its product, Pharos, is used for the treatment of difficult-to-treat, chronic diseases including psoriasis and vitiligo. It operates through the Dermatology and Vascular business segments.